A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Phase 2
Active, not recruiting
NCT02623972
| Condition | Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Dana-Farber Cancer Institute |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 22 participants |
|---|
| Interventions | Eribulin, Adriamycin, Cyclophosphamide |
|---|
| Start date | Feb 26, 2016 |
|---|
| Completion date | May, 2021 |
|---|
| Results posted | Dec 28, 2022 |
|---|
Summary
This research study is studying a drug called eribulin combined with standard treatment as a possible preoperative treatment for HER2 negative inflammatory breast cancer.
Pathologic Complete Response Rate
Assessed after preoperative therapy with either 4 cycles of eribulin mesylate (3 wks) followed by 4 cycles of doxorubicin/cyclophosphamide (2 wks) or after 4 cycles of AC(2 wks) followed by 4 cycles of eribulin(3 wks). As such up to 20 weeks. · percentage of participants
| Arm A: Eribulin Followed by AC | 6.25 percentage of participants |
|---|
| Arm B: AC Followed by Eribulin | 0 percentage of participants |
|---|
| Pathelogic Complete Response Rate | 30 |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.